GlassScriptPhysician profile
David Joseph Gregorio
NPI 1225561954
$4,032.85
in general payments reported to CMS, 2019-2025
41 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $154 · 2023: $883 · 2024: $1,068 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Long Term Medical Supply Or Device Loan: $499 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.01 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $455.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $634.54 | 2024-2025 | |
| Lilly USA, LLC | $303.17 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $261.04 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Celgene Corporation | $253.43 | 2023-2025 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $236.59 | 2023-2025 | Vyloy, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $167.60 | 2023-2025 | Opdivo, Krazati, Augtyro |
| Merck Sharp & Dohme LLC | $159.51 | 2024-2025 | Keytruda, Lynparza |
| Pfizer INC. | $158.10 | 2023-2025 | |
| Shield Therapeutics INC | $130.89 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.75 | 2023-2025 | |
| Incyte Corporation | $126.66 | 2023-2025 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $111.20 | 2024-2025 | Libtayo |
| Seagen INC. | $101.05 | 2022-2023 | Padcev |
| Gilead Sciences, INC. | $99.19 | 2023-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $94.02 | 2023-2025 | Xpovio |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $82.07 | 2023-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $71.60 | 2023-2025 | Venclexta, Tecentriq |
| Rigel Pharmaceuticals, INC. | $70.97 | 2022 | |
| Pharmaessentia USA Corporation | $68.05 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $67.62 | 2024-2025 | Ojjaara, Jemperli |
| Array Biopharma INC | $65.69 | 2025 | Mektovi, Braftovi, Tukysa |
| Eisai INC. | $65.64 | 2023-2025 | |
| Sobi, INC | $47.84 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $46.10 | 2024-2025 | |
| Caris Mpi, INC. | $44.86 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $42.52 | 2023-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $39.34 | 2024 | |
| Pharmacosmos Therapeutics INC. | $39.18 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $36.80 | 2023-2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $32.74 | 2025 | Fruzaqla |
| Beone Medicines USA, INC. | $31.49 | 2025 | Brukinsa |
| Sirtex Medical INC | $25.25 | 2024 | Sir-Spheres Microspheres |
| Geron Corporation | $24.30 | 2025 | Rytelo |
| Tempus Ai, INC | $23.93 | 2024 | |
| Taiho Oncology, INC. | $22.85 | 2025 | |
| Foundation Medicine, INC. | $22.00 | 2023 | |
| Stemline Therapeutics INC. | $20.54 | 2024 | Orserdu |
| Janssen Biotech, INC. | $20.00 | 2024 | Rybrevant |
| Abbvie INC. | $19.72 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.56 | 2023 | Terlivaz |
| Springworks Therapeutics, INC. | $17.45 | 2025 | Gomekli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.